© 2024 HSP News Service, L.L.C.
In the phase III CARTITUDE-4 trial reported in The New England Journal of Medicine, San-Miguel et al found that receipt of ciltacabtagene autoleucel following bridging therapy significantly improved progression-free survival vs standard care in patients with lenalidomide-refractory multiple...
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...
Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...
Additional follow-up of the phase III TROPiCS-02 trial has upheld the progression-free and overall survival benefit seen with sacituzumab govitecan-hziy compared with physician’s choice of treatment in patients with endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast...
In the largest prospective study of patients with primary mediastinal B-cell lymphoma, radiation therapy was omitted in complete responders to immunochemotherapy without compromising outcomes. These findings were presented at the 2023 ASCO Annual Meeting.1 “Mediastinal radiotherapy may be safely...
In the Belgian phase II CHEERS trial reported in JAMA Oncology, Spaas et al evaluated the addition of stereotactic body radiotherapy (SBRT) to anti–PD-1/PD-L1 immune checkpoint inhibitor therapy, with SBRT directed to a maximum of three lesions, in patients with advanced solid tumors. The...
As reported in The New England Journal of Medicine by Jason R. Westin, MD, and colleagues, the overall survival analysis from the phase III ZUMA-7 trial showed significant benefit with axicabtagene ciloleucel vs standard care in patients with early relapsed or refractory large B-cell lymphoma. The...
“Triple-negative breast cancer remains the most challenging subtype to treat because of its aggressive phenotype and limited treatment options,” stated Erica Michelle Stringer-Reasor, MD, who spoke at an education session on current approaches to treatment and future directions during the 2023 ASCO ...
In a French phase II basket trial (AcSé Pembrolizumab) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues investigated the activity and safety of pembrolizumab in patients with rare sarcomas. AcSé Pembrolizumab is an ongoing phase II multitumor study investigating the activity of...
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
As reported in The Lancet by Becker et al, an interim analysis of a European phase II study (ADMEC-O) showed that adjuvant nivolumab was associated with a numeric benefit in disease-free survival vs observation in patients with completely resected Merkel cell carcinoma. Study Details In the...
In the phase II KEYNOTE-B61 trial reported in The Lancet Oncology, Laurence Albiges, MD, PhD, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal cell carcinoma. As stated by the investigators,...
In the phase III CONTACT-03 trial reported in The Lancet, Sumanta Pal, MD, FASCO, and colleagues found that the addition of atezolizumab to cabozantinib did not improve outcomes in patients with renal cell carcinoma whose disease progressed on or after prior immune checkpoint inhibitor treatment....
In a single-institution, phase I, first-in-human trial reported in The Lancet Oncology, Cowan et al found that the combination of the γ-secretase inhibitor (GSI) crenigacestat and B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was tolerable and produced a high...
Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new study published by Bryant et al in Health Affairs. The findings suggested that if vials of immune...
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
As reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, and colleagues, the 7-year follow-up of the phase III KEYNOTE-006 trial has shown a continued overall survival benefit with pembrolizumab vs ipilimumab in patients with advanced melanoma. The primary analysis of the trial...
In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a...
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data...
The formal discussant of the phase II SWOG S1512 trial was Zeynep Eroglu, MD, of the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida. She congratulated Dr. Kendra and her coauthors for conducting a study in such a rare tumor. “I think we can say desmoplastic melanoma ...
The immune checkpoint inhibitor pembrolizumab achieved high response rates in patients with unresectable metastatic desmoplastic melanoma, a rare invasive tumor type, according to the results of the phase II SWOG S1512 trial presented at the 2023 American Association for Cancer Research (AACR)...
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including...
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma,...
Patients with advanced non–small cell lung cancer (NSCLC) may be able to stop receiving immunotherapy at 2 years as long as their cancer hasn’t progressed, according to new findings presented by Sun et al at the 2023 ASCO Annual Meeting (Abstract 9101) and simultaneously published in JAMA Oncology. ...
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel when compared to the current standard-of-care chemoimmunotherapy, according to results of the...
Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).
Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Heather A. Wakelee, MD, of Stanford University, Stanford Cancer Institute, discuss new data supporting neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab as a promising new treatment option for patients with resectable stage II, IIIA, or IIIB (N2) non–small cell lung cancer (NSCLC) (Abstract LBA100).
Ciltacabtagene autoleucel, a B-cell maturation antigen–targeting chimeric antigen receptor (CAR) T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among patients with lenalidomide-refractory disease. Results from the...
Allison Betof Warner, MD, PhD, of Stanford University Medical Center, and Adnan Khattak, MBBS, FRACP, PhD, of Australia’s Hollywood Private Hospital & Edith Cowan University, discuss the use of the mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma, which prolonged distant metastasis–free survival compared with pembrolizumab alone. These results provide further evidence that a personalized neoantigen approach is potentially beneficial (Abstract LBA9503).
Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).
According to the findings of the international phase II DESTINY-PanTumor02 study presented by Funda Meric-Bernstam, MD, and colleagues at the 2023 ASCO Annual Meeting, fam-trastuzumab deruxtecan-nxki (T-DXd) is an effective treatment option for people with difficult-to-treat, HER2-expressing solid...
Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Isabelle L. Ray-Coquard, MD, PhD, of Centre Léon Bérard and the University Claude Bernard Lyon Est, discuss findings from the COLIBRI trial, which showed that, for patients with cervical squamous cell carcinoma, neoadjuvant nivolumab plus ipilimumab is safe and orchestrates de novo immune responses. The 82.5% complete response rate for primary tumors 6 months after standard chemoradiation therapy suggests favorable clinical outcomes (Abstract 5501).
Georgina V. Long, MD, PhD, of Melanoma Institute Australia and The University of Sydney, discusses new data showing that patients with resected stage IIB/C melanoma who were treated with adjuvant nivolumab had prolonged recurrence-free survival compared with placebo across all biomarker subgroups. The baseline biomarkers most predictive of prolonged recurrence-free survival with nivolumab were high interferon gamma score, high tumor mutational burden, CD8 T-cell infiltration, and low C-reactive protein (Abstract 9504).
Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).
Tycel J. Phillips, MD, and Swetha Kambhampati, MD, both of City of Hope National Medical Center, discuss new findings showing that the real-world effectiveness and safety of brexucabtagene autoleucel were similar to data from the pivotal ZUMA-2 trial in patients with relapsed or refractory mantle cell lymphoma, regardless of prior BTK inhibition, bendamustine, or autologous stem cell transplantation (Abstract 7507).
Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).
Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).
The international phase III MIRASOL randomized clinical trial found that mirvetuximab soravtansine-gynx, an antibody and microtubule inhibitor conjugate, significantly improved progression-free and overall survival for patients with platinum-resistant, advanced high-grade epithelial ovarian,...
The immune checkpoint inhibitor nivolumab plus chemotherapy significantly reduced the risk of disease progression and disease-related death compared with standard treatment with the CD30-targeted drug brentuximab vedotin plus chemotherapy in pediatric and adult patients with previously untreated...
The Response Evaluation Criteria in Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories—complete response, partial response, stable disease, or progressive disease—based on the percent of...